Kyselov S.M.

RISK OF UNFAVORABLE COURSE OF ACUTE Q-WAVE MYOCARDIAL INFARCTION UPON THE IMPACT OF ANTICOAGULATION THERAPY

---

About the author:	Kyselov S.M.
Heading	CLINICAL MEDICINE
Type of article	Scentific article
Annotation	The study was aimed at determining the risk of hospital and annual mortality, acute aneurism and thrombus formation inside the left ventricle in patients with Q-wave myocardial infarction upon the impact of unfractionated and low molecular weight heparin after thrombolytic therapy. It was found that survival during the hospital period was significantly higher in the group where unfractionated heparin was used, compared to patients who received fondaparinux. There were no significant differences in the annual survival of patients who received fondaparinux, enoxaparin, and unfractionated heparin. Thus, all three approaches were equally effective for the long-term prognosis of patients with Q-wave myocardial infarction. When comparing the relative risk of aneurysm formation and aneurysm with a left ventricular thrombus in groups of patients with Q-wave myocardial infarction and different anticoagulation therapy, there were no significant differences. Thus, aneurysm of the left ventricle and aneurysm with a left ventricular thrombus occurred with the same frequency in patients with Q-wave myocardial infarction, who used low-molecular or unfractionated heparin. The usage of unfractionated heparin in patients with acute Q-wave myocardial infarction after thrombolytic therapy significantly reduces the risk of hospital mortality by 1.46 times compared with low-molecular-weight heparin. As for annual mortality, the risk of acute aneurysm and aneurysm with thrombus formation, the unfractionated and low-molecular-weight heparin were equally effective.
Tags	acute Q-myocardial infarction, unfractionated heparin, low molecular heparin, thrombolytic therapy
Bibliography	Fedchyshyn N.Ye. Analiz likarnianoi letalnosti vid hostroho infarktu miokarda. Visnyk socialnoi hihiieny ta orhanizacii ochorony zdorovya Ukrainy. 2013; 4 (58): 48-51. [in Ukrainian]. Fedotova LA, Zorin VN, Plastun MIu. Hemostaz, fibrynoliz pry ishemichniy khvorobi sertsia i arterialniy hipertenziyi. Tavricheskii mediko-biolohicheskii vestnik. 2013; 4 (64): 183–186. [in Ukrainian]. Koval EA. Antitromboticheskaya terapiya u patsientov s OKS: suschestvuyut li universalnyie standarty? Zdorovya Ukrainy. 2014; 3: 11. [in Ukrainian]. Sirenko YuM. Medyko-sotsialni problemy kardiolohichnoyi dopomohy v Ukraini: shliahy vyrishennia. Problemy bezperervnoi medychnoi osvity tanauky. 2014; 2: 6-10. [in Ukrainian]. Zaremba YeKh, Salo VM, Myzak OV, Zaremba OV. Klinichnii perebih hostroho infarktu miokarda, uskladnenoho hostroiu livoshlunochkovoiu nedostatnistiu pislia koronarnoho obstezhennia zi stentuvenniam. Simeina medycyna. 2016; 3(65): 30-32. [in Ukrainian]. Antman E.M., Morrow D.A., McCabe C. H. et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med. 2006; 354: 1477–1488. McCann C.J., Menown B.A. New anticoagulant strategies in ST elevation myocardial infarction: Trials and clinical implications. Vasc. Health Risk Managem. 2008; 4 (2): 305–313. Peters R.J., Joyner C., Bassand J. P. et al. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur. Heart J. 2008; 29 (3). 324–331.
Publication of the article	«World of Medicine and Biology» №3(65), 2018 year, 074-077 pages, index UDK 616.127-005.8-085.273-037-07
DOI	10.26724/2079-8334-2018-3-65-74-77